India Plans to Cap Trade Margins on Certain Cancer Drugs, Potentially Reducing Prices by 70%

The cost of cancer treatment remains a significant challenge for patients and families, particularly when treatment requires expensive medicines over extended periods. India's latest proposal to limit trade margins on certain non-scheduled cancer drugs is intended to address the high prices patients face when purchasing these medicines.

Under the reported proposal, trade margins would be capped at 30% for the affected medicines. The government estimates that this could reduce maximum retail prices by as much as 70% in some cases and save patients around ₹2,500 crore annually.

The proposal is particularly relevant to patients who pay for treatment out of pocket. High medicine costs can force families to borrow money, sell assets or delay treatment, potentially affecting continuity of care.

The expected reduction will depend on which medicines are covered and how the pricing rules are implemented. A proposed price cap should not be confused with an immediate reduction in the price of every cancer medicine.

If implemented effectively, the measure could improve affordability and help more patients continue prescribed treatment without interruptions caused by financial difficulties.